AstraZeneca Tries To Halt Apotex Pulmicort Launch

Law360, New York (April 7, 2009, 12:00 AM EDT) -- AstraZeneca Pharmaceuticals LP has asked a federal court to stop Canadian drugmaker Apotex Inc. from launching a generic version of children's asthma medication Pulmicort Respules, one week after the U.S. Food and Drug Administration gave Apotex permission to do so.

In a motion for interim relief filed late Monday in the U.S. District Court for the District of New Jersey, AstraZeneca asked the court to issue a temporary restraining order to bar Apotex from selling its generic version until AstraZeneca's patent infringement suit against the generic-drug...
To view the full article, register now.